Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Kinetics in Medullary Thyroid Cancer Patients Receiving Cabozantinib
Nonlinear mixed effects models were developed to describe the relationship between cabozantinib exposure and target…
Certara2016 年 4 月 27 日
Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates with Estron e-3-Sulfate Transport in Caco-2
Transporter mRNA and protein expression data are used to extrapolate in vitro transporter kinetics to in…
Certara2016 年 4 月 1 日
Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma
The purpose of this study was to characterize the pharmacokinetics of oral trametinib, a first in…
Certara2016 年 4 月 1 日
How modeling and simulation can bring new immuno-oncology treatments to patients
Immuno-oncology, which harnesses the patient's own immune system to fight cancer, is one of the…
Certara2016 年 2 月 16 日
Population PK & Dosing Implications for Cobimetinib in Cancer Patients
A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact…
Certara2015 年 11 月 1 日
Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients
The published OS model and resultant simulations can be leveraged to support Phase II design…
Certara2015 年 9 月 1 日
Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients
Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…
Certara2015 年 7 月 23 日
